Financial reports
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
10-Q
2023 Q1
Quarterly report
2 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
Current reports
8-K
Departure of Directors or Certain Officers
3 Apr 24
8-K
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 Mar 24
8-K
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 Jan 24
8-K
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 Dec 23
8-K
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
13 Dec 23
8-K
Entry into a Material Definitive Agreement
11 Dec 23
8-K
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
9 Nov 23
8-K
Other Events
27 Sep 23
8-K
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
19 Sep 23
8-K
Other Events
12 Sep 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
11 Dec 23
424B5
Prospectus supplement for primary offering
30 Dec 21
S-3/A
Shelf registration (amended)
20 Jul 21
S-3
Shelf registration
15 Jul 21
424B5
Prospectus supplement for primary offering
22 Jul 20
FWP
Free writing prospectus
21 Jul 20
424B5
Prospectus supplement for primary offering
20 Jul 20
424B5
Prospectus supplement for primary offering
20 Apr 20
S-8
Registration of securities for employees
26 Aug 19
424B5
Prospectus supplement for primary offering
9 Jul 19
Proxies
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
19 Apr 21
DEF 14A
Definitive proxy
19 Apr 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
Other
EFFECT
Notice of effectiveness
28 Jul 21
CORRESP
Correspondence with SEC
26 Jul 21
UPLOAD
Letter from SEC
16 Jul 21
CT ORDER
Confidential treatment order
19 Mar 19
EFFECT
Notice of effectiveness
8 Aug 18
CORRESP
Correspondence with SEC
3 Aug 18
UPLOAD
Letter from SEC
1 Aug 18
EFFECT
Notice of effectiveness
20 Oct 15
EFFECT
Notice of effectiveness
20 Oct 15
EFFECT
Notice of effectiveness
29 Jul 15